Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2001

View Archived Issues

Licensing opportunity from NIH: novel posttranscriptional regulatory elements

Licensing opportunity from NIH: acridine derivative for overcoming MDR

Gilead reports product and pipeline highlights for 2000

Nicotine replacement therapy business of Aventis acquired by Pharmacia

Alza acquires Flexeril product and trademark from Merck & Co.

ARGENT technology demonstrates potential in prostate cancer

Medarex and Seattle Genetics to jointly develop human antibody therapeutics

NCX-530 is less toxic than indomethacin to the intestine according to rat studies

Highly potent HIV protease inhibitors from Tibotec may prevent class-wide crossresistance

Magainin and Ludwig Institute further their gene/protein-based alliance

Inhibitor of HIV-1 Rev function acts on receptor-mediated export

Kinetic and clinical data presented in Chicago support further development of DAPD

Approvable letter issued by FDA for GlaxoSmithKline's Avandia in combination with insulin

LDP-02 enters phase II in Canada for ulcerative colitis

Next-generation NNRTI advances to clinical testing in HIV-infected subjects

Second-generation HIV protease inhibitors retain activity against highly resistant strains

KS Biomedix's KSB-301 enters phase II for osteoarthritis

Promising preclinical data reported for Isotechnika immunosuppressant in type 1 diabetes

First oral chemotherapy for treatment of metastatic colorectal cancer approved in Europe

Antisense modulators of integrin beta3 expression

Isis designs antisense oligonucleotides that modulate the expression of G-proteins

Cationic peptides with antibacterial activity described by Canadian university

Novel series for diabetes and related disorders emerges from Tularik-JT collaboration

Panacos and collaborators discuss preclinical profile of anti-HIV candidate

Aventis presents new antibacterial agents derived from moenomycin A

European patent issued to Pfizer for new opioid receptor antagonists

Heterocyclic inhibitors of tyrosine kinase-mediated signal transduction

Kissei and Purdue Pharma terminate licensing agreement for mitiglinide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...